Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RecipharmCobra’s ORT-VACT Delivery Shows Promise | Contract Pharma

What are you searching for?

Sign in
Breaking News

RecipharmCobra’s ORT-VACT Delivery Shows Promise

RecipharmCobra Biologics, in collaboration with the Royal Holloway, University of London and the Universita Cattolica del Sacro Cuore of Rome, Italy, has released the results of a study to develop an oral vaccine against tuberculosis.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

RecipharmCobra Biologics, in collaboration with the Royal Holloway, University of London and the Universita Cattolica del Sacro Cuore of Rome, Italy, has released the results of a study to develop an oral vaccine against tuberculosis.

The study showed that the orally delivered ORT-VAC DNA vaccine produced higher immune responses in mice than the injected DNA vaccine, resulting in a reduction of the TB bacterium Mycobacterium tuberculosis in the lungs of immunized mice. Previous studies in mice using ORT-VAC to deliver protein vaccines have protected against bubonic plague and anthrax.

RecipharmCobra’s ORT-VAC employs live Salmonella bacteria to deliver a TB vaccine orally. The Salmonella bacteria are modified so as not to cause disease. The vaccine is a DNA vaccine, where a gene from a disease-causing microorganism is used to stimulate an immune response.

Simon Saxby, vice resident of Biologics at RecipharmCobra, said, “Using an attenuated bacterium to deliver vaccines orally is a very exciting new area, and the delivery of DNA vaccines has been particularly challenging. The study illustrates the versatility of RecipharmCobra’s ORT-VAC technology to provide a delivery route for needle-free administration of a DNA vaccine. A vaccine based on ORT-VAC could be inexpensive to produce, simple to distribute and easy to administer, which is essential for tackling the disease in developing countries.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters